Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Galecto Inc (GLTO)

Galecto Inc (GLTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,285
  • Shares Outstanding, K 27,113
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,350 K
  • 60-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.58
Trade GLTO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.45
  • Most Recent Earnings $-0.23 on 03/08/24
  • Latest Earnings Date 04/26/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 305.67% ( -438.22%)
  • Historical Volatility 61.59%
  • IV Percentile 50%
  • IV Rank 29.05%
  • IV High 786.30% on 04/08/24
  • IV Low 108.87% on 06/23/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 76
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,038
  • Open Int (30-Day) 798

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.29
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.41
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +43.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6000 +9.22%
on 04/08/24
0.8424 -22.21%
on 03/27/24
-0.1171 (-15.16%)
since 03/18/24
3-Month
0.5612 +16.77%
on 02/05/24
0.9400 -30.29%
on 03/08/24
-0.0211 (-3.12%)
since 01/18/24
52-Week
0.5000 +31.06%
on 11/01/23
3.7000 -82.29%
on 07/26/23
-1.4047 (-68.19%)
since 04/18/23

Most Recent Stories

More News
Nasdaq Futures Climb as Bond Yields Retreat From Decade Highs, Micron Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ23) are trending up +0.44% this morning as U.S. Treasury yields slipped from decade highs, while investors braced for a new round of economic data as well as an earnings...

NQZ23 : 16,530.23s (-0.07%)
CTAS : 666.58 (-0.29%)
AAPL : 167.40 (-0.36%)
GOOGL : 156.59 (+0.72%)
AMZN : 181.45 (+0.09%)
DKNG : 41.70 (-1.21%)
MU : 112.95 (-2.91%)
PAYX : 118.74 (-0.34%)
JEF : 41.60 (+1.00%)
HMB.S.DX : 170.450 (+0.47%)
COST : 714.16 (-0.14%)
CHPT : 1.4200 (+1.43%)
Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Galecto, Inc. (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean...

GLTO : 0.6921 (+2.62%)
All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy

Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GLTO : 0.6921 (+2.62%)
Galecto Reports Second Quarter Operating and Financial Results

BOSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 0.6921 (+2.62%)
Galecto to Participate at Jefferies Healthcare Conference

BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 0.6921 (+2.62%)
Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified Galecto’s oral galectin-3 inhibitor candidate, GB1211, reverses...

GLTO : 0.6921 (+2.62%)
Galecto Reports First Quarter Operating and Financial Results

BOSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 0.6921 (+2.62%)
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor GALACTIC-1 trial on track to deliver top-line results in mid-2023...

GLTO : 0.6921 (+2.62%)
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022 Part 1 of GULLIVER-2 trial completed with positive results as previously...

GLTO : 0.6921 (+2.62%)
UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health

UnitedHealth (UNH) unit Optum's acquisition of Refresh Mental Health comes at a time when demand for behavioral health services is on the rise.

UNH : 492.37 (+2.79%)
CGEN : 1.9200 (+1.05%)
CHNG : 27.49 (+0.26%)
GLTO : 0.6921 (+2.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters...

See More

Key Turning Points

3rd Resistance Point 0.7254
2nd Resistance Point 0.7059
1st Resistance Point 0.6901
Last Price 0.6921
1st Support Level 0.6548
2nd Support Level 0.6353
3rd Support Level 0.6195

See More

52-Week High 3.7000
Fibonacci 61.8% 2.4776
Fibonacci 50% 2.1000
Fibonacci 38.2% 1.7224
Last Price 0.6921
52-Week Low 0.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar